A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)